73219-91-7

Basic information

• Product Name: 3,5-DICHLORO-2,6-DIMETHOXYBENZOIC ACID
• Synonyms: 3,5-DICHLORO-2,6-DIMETHOXYBENZOIC ACID;3,5-DICHLORO-2,6-DIMETHOXYBENZOIC ACID 98%
• CAS NO: 73219-91-7
• Molecular Formula: C₉H₈Cl₂O₄
• Molecular Weight: 251.06
• Product Categories: Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 73219-91-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 99-101°C
• Boiling Point: 362.3 °C at 760 mmHg
• Flash Point: 172.9 °C
• Appearance: /
• Density: 1.443 g/cm³
• Vapor Pressure: 6.98E-06mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: DCM
• CAS DataBase Reference: 3,5-DICHLORO-2,6-DIMETHOXYBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DICHLORO-2,6-DIMETHOXYBENZOIC ACID(73219-91-7)
• EPA Substance Registry System: 3,5-DICHLORO-2,6-DIMETHOXYBENZOIC ACID(73219-91-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• Hazardous Substances Data: 73219-91-7(Hazardous Substances Data)

Usage

Uses

3,5-Dichloro-2,6-dimethoxybenzoic Acid is an intermediate in the synthesis of doapmine D2 receptor antagonists.

InChI:InChI=1/C9H8Cl2O4/c1-14-7-4(10)3-5(11)8(15-2)6(7)9(12)13/h3H,1-2H3,(H,12,13)/p-1

Upstream product

• 131335-43-8 methyl 3,5-dichloro-2,6-dihydroxybenzoate 
• 2150-45-0 methyl 2,6-dihydroxybenzoate 
• 90793-91-2 methyl 3,5-dichloro-2,6-dimethoxybenzoate 
• 1466-76-8 2-6-dimethoxybenzoic acid 

Downstream Products

• 32541-62-1 3,5-dichloro-2,6-dimethoxybenzoic acid chloride 
• 497224-60-9 1,5-dichloro-3-iodo-2,4-dimethoxybenzene 
• 84225-94-5 (-)-A 32559 
• 145351-55-9 (S)-5-<(3,5-dichloro-2-hydroxy-6-methoxybenzamido)methyl>-1-ethyl-2-pyrrolidone 
• 145351-54-8 (S)-5-<(3,5-dichloro-2,6-dimethoxybenzamido)methyl>-1-ethyl-2-pyrrolidone 
• 82935-26-0 A 32559 
• 130880-11-4 3,5-Dichloro-N-[1-(4-chloro-benzyl)-piperidin-4-yl]-2,6-dimethoxy-benzamide 
• 130880-24-9 3,5-Dichloro-N-[1-(4-chloro-benzyl)-piperidin-4-yl]-2-hydroxy-6-methoxy-benzamide 
• 130880-12-5 N-(1-Allyl-piperidin-4-yl)-3,5-dichloro-2,6-dimethoxy-benzamide 
• 130880-25-0 N-(1-Allyl-piperidin-4-yl)-3,5-dichloro-2-hydroxy-6-methoxy-benzamide 
• 130880-13-6 2,6-dimethoxy-3,5-dichloro-N-(1-methyl-4-piperidinyl)benzamide 
• 130880-26-1 3,5-dichloro-6-methoxy-N-(1-methyl-4-piperidinyl)salicylamide 
• 131335-46-1 3,5-dichloro-2,2',3',6,6'-pentamethoxy-4'-methylbenzophenone 
• 131335-44-9 3,5-dichloro-2,2',6,6'-tetramethoxy-4'-methylbenzophenone 

Relevant articles and documents

Synthesis and biological activities of new halophenols

A series of new halophenols were synthesized, and their structures were established on the basis of 1H, 13C NMR and mass spectral data. All of the prepared compounds were screened for their in vitro protein tyrosine kinase (PTK) and vascular smooth muscle cell (VSMC) proliferation inhibitory activity. Twelve halophenols showed significant PTK inhibitory activity, most of them exhibited stronger activities than that of genistein, a positive reference compound. Several halophenols also displayed moderate VSMC proliferation inhibitory activity, compound 8c showed higher activity than that of tetrandrine, a positive reference compound. The preliminary structure-activity relationships of these compounds were investigated and discussed. The results provided a foundation for the action mechanism study and further structure optimization of the halophenols.

Potential Neuroleptic Agents. 2,6-Dialkoxybenzamide Derivatives with Potent Dopamine Receptor Blocking Activities

A series of some novel N-(1-ethyl-2-pyrrolidinylmethyl)benzamides was synthesized and tested for dopamine receptor blockade in vivo by the ability to block the apomorphine syndrome in the rat.Several compounds were considerably more potent than sulpiride as dopamine receptor blockers and displayed low liability to induce extrapyramidal side effects (catalepsy) in the rat.The blockade of dopamine receptor activity in vivo was mainly confined to the levorotatory isomers having the S absolute configuration.The structure-activity relationships are discussed.